Yarrow Bioscience
YARW
53 hedge funds and large institutions have $139M invested in Yarrow Bioscience in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
103% more capital invested
Capital invested by funds: $68.4M → $139M (+$70.6M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
18% more funds holding
Funds holding: 45 → 53 (+8)
4.65% more ownership
Funds ownership: 71.42% → 76.08% (+4.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$6.22M |
| 2 |
O
OrbiMed
New York
|
+$4.22M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$3.74M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.52M |
| 5 |
DM
Deerfield Management
New York
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$5.23M |
| 2 |
Janus Henderson Group
London,
|
-$1.06M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$984K |
| 4 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$696K |
| 5 |
JP Morgan Chase
New York
|
-$576K |
YARW Hedge Fund Activity: Q1 2019 in Review
53 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q1 2019, worth a combined $139M — up 103% from $68.4M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new YARW positions and 3 closed out — a net gain of 8 holders — while 18 added to existing stakes and 11 trimmed.
The largest buyer was First Manhattan, adding an estimated $6.22M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $5.23M sold.
- 53 institutional investors held Yarrow Bioscience (YARW) as of Q1 2019, up from 45 in Q4 2018.
- Funds reported $139M of Yarrow Bioscience stock for Q1 2019, up 103% quarter-over-quarter.
- 11 funds opened new Yarrow Bioscience positions in Q1 2019 and 3 closed out, a net change of +8 holders.
- The largest Yarrow Bioscience buyer in Q1 2019 was First Manhattan, an estimated $6.22M added.
- The largest Yarrow Bioscience seller in Q1 2019 was Novo Holdings A/S, an estimated $5.23M sold.
Based on aggregated 13F filings for Q1 2019.